ACAD
38.03
-0.64
-1.66%
AEMD
0.196
-0.01
-4.6341%
APRI
1.77
-0.01
-0.56%
ARNA
4.64
-0.02
-0.43%
ATEC
1.43
+0.02
+1.42%
CNAT
6.43
-0.22
-3.31%
CRXM
0.35
+0.06
+20.69%
CYTX
1.11
-0.03
-2.63%
DXCM
67.4
-0.53
-0.78%
GNMK
10.86
-2.02
-15.68%
HALO
15.3
-0.22
-1.42%
ILMN
191.16
-1.86
-0.96%
INNV
0.15
0.00
0.00%
INO
10.04
-0.28
-2.76%
ISCO
0.057
-0.001
-0.870%
ISIS
65.33
-0.98
-1.48%
LGND
85.85
-1
-1.15%
LPTN
2.26
+0.03
+1.35%
MBVX
3.55
+0.05
+1.43%
MEIP
2.12
0.00
0.00%
MNOV
4.45
-0.51
-10.28%
MRTX
27.59
-0.21
-0.76%
MSTX
0.472
-0.009
-1.871%
NBIX
42.49
-1.12
-2.57%
NUVA
41.55
-1.18
-2.76%
ONCS
0.31
0.00
-1.59%
ONVO
4.56
-0.16
-3.39%
OREX
7.54
-0.26
-3.33%
OTIC
31.86
-0.52
-1.61%
QDEL
23.7
-0.9
-3.66%
RCPT
167.38
-0.59
-0.35%
RGLS
17.3
+0.12
+0.70%
RMD
71.88
-0.37
-0.51%
SCIE
0.025
-0.002
-7.063%
SPHS
0.81
-0.05
-5.81%
SRNE
11.31
+0.16
+1.43%
TROV
8.53
+1.43
+20.14%
VICL
0.94
-0.01
-1.05%
VOLC
17.99
0.00
0.00%
ZGNX
1.58
-0.02
-1.25%
ACAD
38.03
-0.64
-1.66%
AEMD
0.196
-0.01
-4.6341%
APRI
1.77
-0.01
-0.56%
ARNA
4.64
-0.02
-0.43%
ATEC
1.43
+0.02
+1.42%
CNAT
6.43
-0.22
-3.31%
CRXM
0.35
+0.06
+20.69%
CYTX
1.11
-0.03
-2.63%
DXCM
67.4
-0.53
-0.78%
GNMK
10.86
-2.02
-15.68%
HALO
15.3
-0.22
-1.42%
ILMN
191.16
-1.86
-0.96%
INNV
0.15
0.00
0.00%
INO
10.04
-0.28
-2.76%
ISCO
0.057
-0.001
-0.870%
ISIS
65.33
-0.98
-1.48%
LGND
85.85
-1
-1.15%
LPTN
2.26
+0.03
+1.35%
MBVX
3.55
+0.05
+1.43%
MEIP
2.12
0.00
0.00%
MNOV
4.45
-0.51
-10.28%
MRTX
27.59
-0.21
-0.76%
MSTX
0.472
-0.009
-1.871%
NBIX
42.49
-1.12
-2.57%
NUVA
41.55
-1.18
-2.76%
ONCS
0.31
0.00
-1.59%
ONVO
4.56
-0.16
-3.39%
OREX
7.54
-0.26
-3.33%
OTIC
31.86
-0.52
-1.61%
QDEL
23.7
-0.9
-3.66%
RCPT
167.38
-0.59
-0.35%
RGLS
17.3
+0.12
+0.70%
RMD
71.88
-0.37
-0.51%
SCIE
0.025
-0.002
-7.063%
SPHS
0.81
-0.05
-5.81%
SRNE
11.31
+0.16
+1.43%
TROV
8.53
+1.43
+20.14%
VICL
0.94
-0.01
-1.05%
VOLC
17.99
0.00
0.00%
ZGNX
1.58
-0.02
-1.25%
Home » Bio: Joseph E. Payne

Bio: Joseph E. Payne

Joseph E. Payne brings with him an exceptional track record of ushering novel therapeutics to the clinic including successful experience developing sophisticated targeted RNAi nanoparticle technologies.  Joseph’s background includes over 20 years of successful drug discovery experience at Merck Research Labs, DuPont Pharmaceuticals, Bristol-Myers Squibb, Kalypsys, and Nitto Denko as evidenced by over 40 publications and patents, and 7 FDA-approved IND clinical candidates.  His academic training includes BYU (magna cum laude, Chemistry and Physics), University of Calgary (Synthetic Organic Chemistry), and MIT Sloan School of Management (Executive Training, Supply Chain and Logistics.